Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
GUANGZHOU, China, May 5, 2025 ~ Fangzhou Inc., a prominent Internet healthcare solutions company, has recently announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform. This development provides expanded treatment options for patients suffering from chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The approval of Iclusig® in China in September 2024 has been a significant milestone for the company. This drug has shown remarkable efficacy against T315I-mutated BCR::ABL1 disease, which is resistant to first and second generation TKIs. The OPTIC trial has demonstrated a four-year survival rate of 88% among certain patient cohorts.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou Inc., expressed his enthusiasm about this achievement, stating, "As a platform focused on patient-centered healthcare, we are committed to bringing innovative treatments such as Iclusig® to Chinese patients through our digital healthcare ecosystem."
More on The PennZone
Fangzhou Inc. has established strong partnerships with leading domestic and multinational pharmaceutical companies. With a comprehensive drug supply chain spanning multiple therapeutic areas including oncology, liver disease, and cardiovascular diseases, the company now offers over 210,000 drug SKUs to meet the diverse needs of chronic disease patients. By utilizing AI, big data, and cloud computing technologies, Fangzhou Inc. is continuously enhancing its health management services. Additionally, the company's proprietary "AI Personal Health Assistant" and other innovative tools aim to improve medication safety and enhance treatment adherence.
The company's focus on AI-enabled full-cycle healthcare sets it apart from its competitors. Through its "AI + H2H Smart Healthcare Platform," patients can access online medical consultations and personalized health recommendations designed to enhance their quality of life. By combining access to innovative drugs with precision health services, Fangzhou Inc. is revolutionizing full-cycle health management through its "technology + care" approach. In the future, the company plans to deepen AI integration within its Internet-based medical services and expand partnerships with leading global pharmaceutical companies to bring more breakthrough treatments and cutting-edge innovations to patients and their families.
More on The PennZone
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.
For further inquiries or interviews, please contact Xingwei Zhao, Associate Director of Public Relations at Fangzhou Inc., via email at [insert email address].
Disclaimer: This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements due to various factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
The approval of Iclusig® in China in September 2024 has been a significant milestone for the company. This drug has shown remarkable efficacy against T315I-mutated BCR::ABL1 disease, which is resistant to first and second generation TKIs. The OPTIC trial has demonstrated a four-year survival rate of 88% among certain patient cohorts.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou Inc., expressed his enthusiasm about this achievement, stating, "As a platform focused on patient-centered healthcare, we are committed to bringing innovative treatments such as Iclusig® to Chinese patients through our digital healthcare ecosystem."
More on The PennZone
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
Fangzhou Inc. has established strong partnerships with leading domestic and multinational pharmaceutical companies. With a comprehensive drug supply chain spanning multiple therapeutic areas including oncology, liver disease, and cardiovascular diseases, the company now offers over 210,000 drug SKUs to meet the diverse needs of chronic disease patients. By utilizing AI, big data, and cloud computing technologies, Fangzhou Inc. is continuously enhancing its health management services. Additionally, the company's proprietary "AI Personal Health Assistant" and other innovative tools aim to improve medication safety and enhance treatment adherence.
The company's focus on AI-enabled full-cycle healthcare sets it apart from its competitors. Through its "AI + H2H Smart Healthcare Platform," patients can access online medical consultations and personalized health recommendations designed to enhance their quality of life. By combining access to innovative drugs with precision health services, Fangzhou Inc. is revolutionizing full-cycle health management through its "technology + care" approach. In the future, the company plans to deepen AI integration within its Internet-based medical services and expand partnerships with leading global pharmaceutical companies to bring more breakthrough treatments and cutting-edge innovations to patients and their families.
More on The PennZone
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.
For further inquiries or interviews, please contact Xingwei Zhao, Associate Director of Public Relations at Fangzhou Inc., via email at [insert email address].
Disclaimer: This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements due to various factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Filed Under: Business
0 Comments
Latest on The PennZone
- Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
- GormanSquared Announces Provisional Patent
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- Chewy Chums™ Launches NeverBite™ on Kickstarter
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
- Immorta Bio to Present SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting
- "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando